Research Site

Rockville Centre, New York 11570

1 studies enrolling now · 12 studies all time

What they study most

APOL1-Mediated Kidney Disease, Asthma, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Breast Cancer Metastatic, COPD, Carcinoma, Chronic Kidney Disease and Hypertension, Chronic Obstructive Pulmonary Disease, Metastases, Neoplasm, Non-small-cell Lung

Studies at this site

• Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease — Recruiting now
• A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. — Running, not enrolling
• Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. — Completed
• Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) — Completed
• Observational Study of Obstructive Lung Disease (NOVELTY) — Completed
• A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma — Completed
• A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection — Completed
• A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg — Completed
• A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents — Completed
• A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo — Completed
• Iressa Expanded Access Program (EAP) — Completed
• New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma — Completed